The DOI matches its Crossref record; 136 of the 139 references it cites were found in a registry or an index.
The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia
Open accessAbstract
The World Health Organization (WHO) classification of tumors of the hematopoietic and lymphoid tissues was last updated in 2008. Since then, there have been numerous advances in the identification of unique biomarkers associated with some myeloid neoplasms and acute leukemias, largely derived from gene expression analysis and next-generation sequencing that can significantly improve the diagnostic criteria as well as the prognostic relevance of entities currently included in the WHO classification and that also suggest new entities that should be added. Therefore, there is a clear need for a revision to the current classification. The revisions to the categories of myeloid neoplasms and acute leukemia will be published in a monograph in 2016 and reflect a consensus of opinion of hematopathologists, hematologists, oncologists, and geneticists. The 2016 edition represents a revision of the prior classification rather than an entirely new classification and attempts to incorporate new clinical, prognostic, morphologic, immunophenotypic, and genetic data that have emerged since the last edition. The major changes in the classification and their rationale are presented here.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“EPI-CT also evaluated risk using the revised World Health Organization (WHO) classification of hematopoietic and lymphoid tissue malignancies27,28.”
From Risk of hematological malignancies from CT radiation exposure in children, adolescents and young adults (2023) · cites this paper as [27]
The cited source says what the claim attributes to it.
In the citing paper
“For CML patients, disease diagnosis and progression were defined according to the 2016 edition of World Health Organization criteria.75”
From Integrated drug profiling and CRISPR screening identify BCR::ABL1-independent vulnerabilities in chronic myeloid leukemia (2024) · cites this paper as [75]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Genomic and Epigenomic Landscapes of Adult De Novo Acute Myeloid Leukemia
The Cancer Genome Atlas Research Network (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1301689 · Cited by 5,078
Age-related clonal hematopoiesis associated with adverse outcomes
Jaiswal, S., Fontanillas, P., Flannick, J., Manning, A., Grauman, P. V., Mar, B. G., Lindsley, R. C., Mermel, C. H., Burtt, N., Chavez, A., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1408617 · Cited by 4,841
Vardiman, J. W., Thiele, J., Arber, D. A., Brunning, R. D., Borowitz, M. J., Porwit‐MacDonald, A., Harris, N. L., Beau, M. M. L., Hellström‐Lindberg, E., Tefferi, A., et al. (2009) · Blood · doi:10.1182/blood-2009-03-209262 · Cited by 4,532
Self-citationClonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence
Genovese, G., Kähler, A. K., Handsaker, R. E., Lindberg, J., Rose, S. A., Bakhoum, S. F., Chambert, K., Mick, E., Neale, B. M., Fromer, M., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1409405 · Cited by 3,531
Döhner, H., Weisdorf, D. J., & Bloomfield, C. D. (2015) · New England Journal of Medicine · doi:10.1056/nejmra1406184 · Cited by 3,468
Self-citationRevised International Prognostic Scoring System for Myelodysplastic Syndromes
Greenberg, P. L., Tuechler, H., Schanz, J., Sanz, G. F., Garcia‐Manero, G., Solé, F. G., Bennett, J. M., Bowen, D., Fenaux, P., Dreyfus, F., et al. (2012) · Blood · doi:10.1182/blood-2012-03-420489 · Cited by 3,224
Self-citationEuropean LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013
Baccarani, M., Deininger, M. W., Rosti, G., Hochhaus, A., Soverini, S., Apperley, J. F., Cervantes, F., Clark, R. E., Cortes, J. E., Guilhot, F., et al. (2013) · Blood · doi:10.1182/blood-2013-05-501569 · Cited by 2,011
Prognostic Relevance of Integrated Genetic Profiling in Acute Myeloid Leukemia
Patel, J. P., Gönen, M., Figueroa, M. E., Fernandez, H. F., Sun, Z., Racevskis, J., Vlierberghe, P. V., Dolgalev, I., Thomas, S., Aminova, O., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1112304 · Cited by 1,990
Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes
Steensma, D. P., Bejar, R., Jaiswal, S., Lindsley, R. C., Sekeres, M. A., Hasserjian, R. P., & Ebert, B. L. (2015) · Blood · doi:10.1182/blood-2015-03-631747 · Cited by 1,971
Self-citationGrimwade, D. J., Hills, R. K., Moorman, A. V., Walker, H., Chatters, S., Goldstone, A. H., Wheatley, K., Harrison, C. J., & Burnett, A. K. (2010) · Blood · doi:10.1182/blood-2009-11-254441 · Cited by 1,936
Cited by
Sorted by citations
Items 101–200 of 1,020
Pratz, K. W., Jonas, B. A., Pullarkat, V. A., Thirman, M. J., Garcia, J. S., Döhner, H., Récher, C., Fiedler, W., Yamamoto, K., Wang, J., et al. (2024) · American Journal of Hematology · doi:10.1002/ajh.27246 · Cited by 240
Agarwal, S. K., Dinardo, C. D., Potluri, J., Dunbar, M., Kantarjian, H. M., Humerickhouse, R. A., Wong, S. L., Menon, R. M., Konopleva, M. Y., & Salem, A. H. (2017) · Clinical Therapeutics · doi:10.1016/j.clinthera.2017.01.003 · Cited by 238
Tefferi, A., & Barbui, T. (2018) · American Journal of Hematology · doi:10.1002/ajh.25303 · Cited by 240
Measurable residual disease testing in acute myeloid leukaemia
Hourigan, C. S., Gale, R. P., Gormley, N. J., Ossenkoppele, G. J., & Walter, R. B. (2017) · Leukemia · doi:10.1038/leu.2017.113 · Cited by 239
Sallman, D. A., Komrokji, R., Vaupel, C., Cluzeau, T., Geyer, S. M., McGraw, K. L., Al Ali, N. H., Lancet, J., McGinniss, M. J., Nahas, S., et al. (2016) · Leukemia · doi:10.1038/leu.2015.304 · Cited by 231
Tefferi, A., Guglielmelli, P., Lasho, T. L., Coltro, G., Finke, C. M., Loscocco, G. G., Sordi, B., Szuber, N., Rotunno, G., Pacilli, A., et al. (2020) · British Journal of Haematology · doi:10.1111/bjh.16380 · Cited by 232
Tefferi, A., & Barbui, T. (2016) · American Journal of Hematology · doi:10.1002/ajh.24607 · Cited by 233
Leukaemia: a model metastatic disease
Whiteley, A. E., Price, T. T., Cantelli, G., & Sipkins, D. A. (2021) · Nature reviews. Cancer · doi:10.1038/s41568-021-00355-z · Cited by 241
“Diseasespecific expression of VEGF and its receptors in AML cells: possible autocrine pathway of VEGF/type1 receptor of VEGF in t(15;17) AML and VEGF/type2 receptor of VEGF in t(8;21) AML.”
BackgroundTargeting multiple signaling pathways: the new approach to acute myeloid leukemia therapy
Carter, J. L., Hege-Hurrish, K., Yang, J., Kalpage, H. A., Su, Y., Edwards, H. J., Hüttemann, M., Taub, J. W., & Ge, Y. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00361-x · Cited by 230
Bersanelli, M., Travaglino, E., Meggendorfer, M., Matteuzzi, T., Sala, C., Mosca, E., Chiereghin, C., Nanni, N. D., Gnocchi, M., Zampini, M., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.20.01659 · Cited by 228
“Despite recent progress in understanding the disease biology, MDS with isolated 5q deletion is the only category defined by a specific genomic abnormality in theWHO classification(2) and only few genotypephenotype associations have been reported until now, mainly referring to the close relationship betweenmutations in…”
BackgroundMethodInfluentialMyelodysplastic syndromes: 2023 update on diagnosis, risk‐stratification, and management
Garcia‐Manero, G. (2023) · American Journal of Hematology · doi:10.1002/ajh.26984 · Cited by 241
Genomic profiling for clinical decision making in myeloid neoplasms and acute leukemia
Duncavage, E. J., Bagg, A., Hasserjian, R. P., Dinardo, C. D., Godley, L. A., Iacobucci, I., Jaiswal, S., Malcovati, L., Vannucchi, A. M., Patel, K. P., et al. (2022) · Blood · doi:10.1182/blood.2022015853 · Cited by 235
Self-citationTargeted deep sequencing in primary myelofibrosis
Tefferi, A., Lasho, T. L., Finke, C. M., Elala, Y. C., Hanson, C. A., Ketterling, R. P., Gangat, N., & Pardanani, A. D. (2016) · Blood Advances · doi:10.1182/bloodadvances.2016000208 · Cited by 220
Molecular hybridization: a powerful tool for multitarget drug discovery
Pinheiro, P. D. S. M., Franco, L. S., Montagnoli, T. L., & Fraga, C. A. M. (2024) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2024.2322990 · Cited by 230
“These targets belong to the kinase family of proteins, modulate signal transduction in cells, and play a key role in hematological malignancies [99].”
Walter, R. B., Gyurkocza, B., Storer, B. E., Godwin, C. D., Pagel, J. M., Buckley, S. A., Sorror, M. L., Wood, B. L., Storb, R. F., Appelbaum, F. R., et al. (2014) · Leukemia · doi:10.1038/leu.2014.173 · Cited by 217
Brown, P. A., Inaba, H., Annesley, C., Beck, J. C., Colace, S. I., Dallas, M. H., DeSantes, K. B., Kelly, K. M., Kitko, C. L., Lacayo, N. J., et al. (2020) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2020.0001 · Cited by 229
Monogenic and polygenic inheritance become instruments for clonal selection
Loh, P., Genovese, G., & McCarroll, S. A. (2020) · Nature · doi:10.1038/s41586-020-2430-6 · Cited by 210
Life histories of myeloproliferative neoplasms inferred from phylogenies.
Williams, N., Lee, J., Mitchell, E., Moore, L., Baxter, E. J., Hewinson, J., Dawson, K. J., Menzies, A. H., Godfrey, A. L., Green, A. R., et al. (2022) · RePEc: Research Papers in Economics · doi:10.17863/cam.80309 · Cited by 216
Gotlib, J. (2017) · American journal of hematology/oncology · doi:10.1002/ajh.24880 · Cited by 187
Germline DDX41 mutations define a significant entity within adult MDS/AML patients
Sébert, M., Passet, M., Raimbault, A., Rahmé, R., Raffoux, E., de Fontbrune, F. S., Cerrano, M., Quentin, S., Vasquez, N., Costa, M. D., et al. (2019) · Blood · doi:10.1182/blood.2019000909 · Cited by 212
The genomic landscape of pediatric myelodysplastic syndromes
Schwartz, J. R., Ma, J., Westover, T., Walsh, M. P., Wang, S., Bryant, V. L., Song, G., Wu, G., Easton, J. B., Kesserwan, C. A., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-01590-5 · Cited by 213
Myelodysplastic syndromes: 2018 update on diagnosis, risk‐stratification and management
Bravo, G. M., & Garcia‐Manero, G. (2017) · American Journal of Hematology · doi:10.1002/ajh.24930 · Cited by 212
Biological and clinical consequences of NPM1 mutations in AML
Heath, E. M., Chan, S. M., Minden, M. D., Murphy, T., Shlush, L. I., & Schimmer, A. D. (2017) · Leukemia · doi:10.1038/leu.2017.30 · Cited by 224
MYC: a multipurpose oncogene with prognostic and therapeutic implications in blood malignancies
Ahmadi, S. E., Rahimi, S., Zarandi, B., Chegeni, R., & Safa, M. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01111-4 · Cited by 223
“Burkitt lymphoma invariably shows a translocation of MYC gene to the immunoglobulin gene loci [549].”
BackgroundSubtype-specific 3D genome alteration in acute myeloid leukaemia
Xu, J., Song, F., Lyu, H., Kobayashi, M., Zhang, B., Zhao, Z., Hou, Y., Wang, X., Luan, Y., Jia, B., et al. (2022) · Nature · doi:10.1038/s41586-022-05365-x · Cited by 208
Tesi, B., Davidsson, J., Voß, M., Rahikkala, E., Holmes, T. D., Chiang, S. C. C., Komulainen‐Ebrahim, J., Gorcenco, S., Nilsson, A. R., Ripperger, T., et al. (2017) · Blood · doi:10.1182/blood-2016-10-743302 · Cited by 209
Goldschmidt, H., Lokhorst, H. M., Mai, E. K., van der Holt, B., Blau, I. W., Zweegman, S., Weisel, K. C., Vellenga, E., Pfreundschuh, M., Kersten, M. J., et al. (2018) · Leukemia · doi:10.1038/leu.2017.211 · Cited by 200
Venetoclax Plus Gilteritinib for FLT3 -Mutated Relapsed/Refractory Acute Myeloid Leukemia
Daver, N. G., Perl, A. E., Maly, J. J., Levis, M. J., Ritchie, E. K., Litzow, M. R., McCloskey, J. K., Smith, C. C., Schiller, G. J., Bradley, T., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.22.00602 · Cited by 203
“Anemia 3 (43) 3 (43) 3 (38) 2 (25) 23 (43) 20 (37) 26 (43) 23 (38)”
InfluentialMutated nucleophosmin 1 as immunotherapy target in acute myeloid leukemia
van der Lee, D. I., Reijmers, R. M., Honders, M. W., Hagedoorn, R. S., de Jong, R. C. M., Kester, M. G. D., van der Steen, D. M., de Ru, A. H., Kweekel, C., Bijen, H. M., et al. (2019) · Journal of Clinical Investigation · doi:10.1172/jci97482 · Cited by 207
Acute Myeloid Leukemia, Version 3.2023, NCCN Clinical Practice Guidelines in Oncology
Pollyea, D. A., Altman, J. K., Assi, R. E., Bixby, D. L., Fathi, A. T., Foran, J. M., Gojo, I., Hall, A. C., Jonas, B. A., Kishtagari, A., et al. (2023) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2023.0025 · Cited by 200
Translation of cytoplasmic UBA1 contributes to VEXAS syndrome pathogenesis
Ferrada, M. A., Savic, S., Cardona, D. O., Collins, J. C., Alessi, H. D., Gutierrez‐Rodrigues, F., Kumar, D. B. U., Wilson, L., Goodspeed, W. J., Topilow, J. S., et al. (2022) · Blood · doi:10.1182/blood.2022016985 · Cited by 199
Rungjirajittranon, T., Owattanapanich, W., Ungprasert, P., Siritanaratkul, N., & Ruchutrakool, T. (2019) · BMC Cancer · doi:10.1186/s12885-019-5387-9 · Cited by 197
TP53 mutations in myelodysplastic syndromes and secondary AML confer an immunosuppressive phenotype
Sallman, D. A., McLemore, A. F., Aldrich, A. L., Komrokji, R. S., McGraw, K. L., Dhawan, A., Geyer, S., Hou, H.-A., Eksioglu, E. A., Sullivan, A., et al. (2020) · Blood · doi:10.1182/blood.2020006158 · Cited by 196
Zeidan, A. M., Shallis, R. M., Wang, R., Davidoff, A. J., & Ma, X. (2018) · Blood Reviews · doi:10.1016/j.blre.2018.09.001 · Cited by 205
Valent, P., Orazi, A., Steensma, D. P., Ebert, B. L., Haase, D. T., Malcovati, L., van de Loosdrecht, A. A., Haferlach, T., Westers, T. M., Wells, D. A., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.19008 · Cited by 197
Self-citationGenetics and prognosis of ALL in children vs adults
Roberts, K. G. (2018) · Hematology · doi:10.1182/asheducation-2018.1.137 · Cited by 204
Unified classification and risk-stratification in Acute Myeloid Leukemia
Tazi, Y., Ossa, J. A., Zhou, Y., Bernard, E., Thomas, I., Gilkes, A., Freeman, S. D., Pradat, Y., Johnson, S. J., Hills, R. K., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-32103-8 · Cited by 195
Zhou, Y., Othus, M. K. D., Araki, D., Wood, B. L., Radich, J. P., Halpern, A. B., Mielcarek, M. B., Estey, E. H., Appelbaum, F. R., & Walter, R. B. (2016) · Leukemia · doi:10.1038/leu.2016.46 · Cited by 192
Cordeiro, P. G., Ghione, P., Ni, A., Hu, Q. Y., Ganesan, N., Galasso, N., Doǧan, A., & Horwitz, S. M. (2020) · Journal of Plastic Reconstructive & Aesthetic Surgery · doi:10.1016/j.bjps.2019.11.064 · Cited by 192
Clinical consequences of clonal hematopoiesis of indeterminate potential
Steensma, D. P. (2018) · Blood Advances · doi:10.1182/bloodadvances.2018020222 · Cited by 194
Genetic predisposition to hematologic malignancies: management and surveillance
Godley, L. A., & Shimamura, A. (2017) · Blood · doi:10.1182/blood-2017-02-735290 · Cited by 192
Shomali, W. E., & Gotlib, J. R. (2019) · American Journal of Hematology · doi:10.1002/ajh.25617 · Cited by 190
Stahl, M. F., Menghrajani, K. N., Derkach, A., Chan, A. C. L., Xiao, W., Glass, J. L., King, A. C., Daniyan, A. F., Famulare, C. A., Cuello, B. M., et al. (2021) · Blood Advances · doi:10.1182/bloodadvances.2020003734 · Cited by 191
“Partial remission 7/86 (8) 4/35 (16) 1/20 (5) 2/27 (7) .”
Ørskov, A. D., Treppendahl, M. B., Skovbo, A., Holm, M. S., Friis, L. S., Hokland, M., & Grønbæk, K. (2015) · Oncotarget · doi:10.18632/oncotarget.3324 · Cited by 190
Innate immune pathways and inflammation in hematopoietic aging, clonal hematopoiesis, and MDS
Trowbridge, J. J., & Starczynowski, D. T. (2021) · Journal of Experimental Medicine · doi:10.1084/jem.20201544 · Cited by 189
Clinical consequences of clonal hematopoiesis of indeterminate potential
Steensma, D. P. (2018) · Hematology · doi:10.1182/asheducation-2018.1.264 · Cited by 189
Oberg, J. A., Bender, J. G., Sulis, M. L., Pendrick, D., Sireci, A. N., Hsiao, S. J., Turk, A. T., Cruz, F. S. D., Hibshoosh, H. H., Remotti, H. E., et al. (2016) · Genome Medicine · doi:10.1186/s13073-016-0389-6 · Cited by 188
Guglielmelli, P., Pacilli, A., Rotunno, G., Rumi, E., Rosti, V., Delaini, F., Maffioli, M., Fanelli, T., Pancrazzi, A., Pietra, D., et al. (2017) · Blood · doi:10.1182/blood-2017-01-761999 · Cited by 187
Self-citationMyelodysplastic syndromes: 2021 update on diagnosis, risk stratification and management
Garcia‐Manero, G., Chien, K. S., & Bravo, G. M. (2020) · American Journal of Hematology · doi:10.1002/ajh.25950 · Cited by 192
Psaila, B., Wang, G., Rodriguez-Meira, A., Li, R., Heuston, E. F., Murphy, L., Yee, D., Hitchcock, I. S., Sousos, N., O’Sullivan, J., et al. (2020) · Molecular Cell · doi:10.1016/j.molcel.2020.04.008 · Cited by 185
Jonas, B. A., & Pollyea, D. A. (2019) · Leukemia · doi:10.1038/s41375-019-0612-8 · Cited by 184
Kennedy, A. L., Myers, K. C., Bowman, J. R., Gibson, C. J., Camarda, N. D., Furutani, E., Muscato, G. M., Klein, R. H., Ballotti, K., Liu, S., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-21588-4 · Cited by 197
“To quantify the technical dropout, we defined the proportion of targeted mutations, which were defined as those (1) present in the bulk sequencing and (2) located in designable amplicons, for which genotyping was successful.”
BackgroundNatural history of GATA2 deficiency in a survey of 79 French and Belgian patients
Donadieu, J., Lamant, M., Fieschi, C., de Fontbrune, F. S., Caye‐Eude, A., Ouachée-Chardin, M., Beaupain, B., Bustamante, J. C., Poirel, H. A., Isidor, B., et al. (2018) · Haematologica · doi:10.3324/haematol.2017.181909 · Cited by 183
International Consensus Classification of acute lymphoblastic leukemia/lymphoma
Duffield, A. S., Mullighan, C. G., & Borowitz, M. J. (2022) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-022-03448-8 · Cited by 183
“Most entities from the 2016 WHO are retained, but there are several modifications that incorporate findings from recent genomic studies [2].”
BackgroundSelf-citationHow I diagnose and manage individuals at risk for inherited myeloid malignancies
The University of Chicago Hematopoietic Malignancies Cancer Risk Team (2016) · Blood · doi:10.1182/blood-2016-05-670240 · Cited by 186
Enhancer Hijacking Drives Oncogenic BCL11B Expression in Lineage-Ambiguous Stem Cell Leukemia
Montefiori, L. E., Bendig, S., Gu, Z., Chen, X., Pölönen, P., Ma, X., Murison, A., Zeng, A. G. X., García‐Prat, L., Dickerson, K. M., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-0145 · Cited by 189
Chronic Myeloid Leukemia: A Model Disease of the Past, Present and Future
Minciacchi, V. R., Kumar, R., & Krause, D. S. (2021) · Cells · doi:10.3390/cells10010117 · Cited by 195
“According to criteria by the World Health Organization, 10–19% blasts in peripheral blood or bone marrow are counted as AP, while > 20% blasts are considered a criterion for BC [19] (Figure 1).”
MethodSystemic mastocytosis in adults: 2021 Update on diagnosis, risk stratification and management
Pardanani, A. D. (2021) · American Journal of Hematology · doi:10.1002/ajh.26118 · Cited by 181
“variant of SM and bone marrow mastocytosis (BMM) as a provisional variant.(1,2) Therefore, SSM is characterized by a high burden of MC defined by the presence of ≥2 “B-findings” (Tables 1 and 2; Figure 2),”
BackgroundMethodInfluentialPlatzbecker, U., Porta, M. G. D., Santini, V., Zeidan, A. M., Komrokji, R. S., Shortt, J., Valcárcel, D., Jonasova, A. T., Dimicoli, S., Tiong, I. S., et al. (2023) · The Lancet · doi:10.1016/s0140-6736(23)00874-7 · Cited by 187
Binder, S., Luciano, M., & Horejs-Hoeck, J. (2018) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2018.08.004 · Cited by 190
Somatic and germline genomics in paediatric acute lymphoblastic leukaemia
Pui, C., Nichols, K. E., & Yang, J. J. J. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0136-6 · Cited by 189
Yacoub, A., Mascarenhas, J. O., Kosiorek, H., Prchal, J. T., Berenzon, D., Baer, M. R., Ritchie, E. K., Silver, R. T., Kessler, C. M., Winton, E. F., et al. (2019) · Blood · doi:10.1182/blood.2019000428 · Cited by 188
Shomali, W. E., & Gotlib, J. R. (2021) · American Journal of Hematology · doi:10.1002/ajh.26352 · Cited by 183
“WHO scheme of myeloid neoplasms and reaffirmed in 2016 (Table 1).(19,20) In recognition of the growing list of recurrent, molecularly defined primary eosinophilias resulting from fusion tyrosine kinase genes, the major category “Myeloid/lymphoid neoplasms with”
BackgroundInfluentialMyeloproliferative neoplasms: A decade of discoveries and treatment advances
Tefferi, A. (2015) · American Journal of Hematology · doi:10.1002/ajh.24221 · Cited by 186
Shiozawa, Y., Malcovati, L., Gallì, A., Sato‐Otsubo, A., Kataoka, K., Sato, Y., Watatani, Y., Suzuki, H., Yoshizato, T., Yoshida, K., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-06063-x · Cited by 179
Self-citationThe bone marrow microenvironment – Home of the leukemic blasts
Shafat, M. S., Gnaneswaran, B., Bowles, K. M., & Rushworth, S. A. (2017) · Blood Reviews · doi:10.1016/j.blre.2017.03.004 · Cited by 185
Tefferi, A., & Pardanani, A. D. (2019) · New England Journal of Medicine · doi:10.1056/nejmcp1816082 · Cited by 175
Loss of EZH2 Reprograms BCAA Metabolism to Drive Leukemic Transformation
Gu, Z., Liu, Y., Cai, F., Patrick, M., Zmajkovic, J., Cao, H., Zhang, Y., Tasdogan, A., Chen, M., Qi, L., et al. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-0152 · Cited by 173
Systemic mastocytosis in adults: 2019 update on diagnosis, risk stratification and management
Pardanani, A. D. (2018) · American Journal of Hematology · doi:10.1002/ajh.25371 · Cited by 173
Clinical Implications of Genetic Mutations in Myelodysplastic Syndrome
Kennedy, J. A., & Ebert, B. L. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.71.0806 · Cited by 175
Cytarabine and daunorubicin for the treatment of acute myeloid leukemia
Murphy, T., & Yee, K. W. L. (2017) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2017.1391216 · Cited by 180
Myeloid malignancies and the microenvironment
Korn, C., & Méndez‐Ferrer, S. (2016) · Blood · doi:10.1182/blood-2016-09-670224 · Cited by 170
Personalized prediction model to risk stratify patients with myelodysplastic syndromes
Nazha, A., Komrokji, R., Meggendorfer, M., Jia, X., Radakovich, N., Shreve, J., Hilton, C. B., Nagata, Y., Hamilton, B. K., Mukherjee, S., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.20.02810 · Cited by 169
Pollyea, D. A., Pratz, K. W., Letai, A. G., Jonas, B. A., Wei, A. H., Pullarkat, V. A., Konopleva, M. Y., Thirman, M. J., Arellano, M. L., Becker, P. S., et al. (2020) · American Journal of Hematology · doi:10.1002/ajh.26039 · Cited by 167
Szuber, N., Mudireddy, M., Nicolosi, M., Penna, D., Vallapureddy, R. R., Lasho, T. L., Finke, C. M., Begna, K. H., Elliott, M. A., Hook, C. C., et al. (2019) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2018.08.022 · Cited by 172
Metabolic Plasticity of Acute Myeloid Leukemia
Kreitz, J., Schönfeld, C., Seibert, M., Stolp, V., Alshamleh, I., Oellerich, T., Steffen, B., Schwalbe, H., Schnütgen, F., Kurrle, N., et al. (2019) · Cells · doi:10.3390/cells8080805 · Cited by 177
Taube, F., Georgi, J.-A., Krämer, M., Stasik, S., Middeke, J. M., Röllig, C., Krug, U. O., Krämer, A., Scholl, S., Hochhaus, A., et al. (2021) · Blood · doi:10.1182/blood.2020009680 · Cited by 167
McMullin, M. F., Harrison, C. N., Ali, S., Cargo, C. A., Chen, F. E., Ewing, J. C., Garg, M. K., Godfrey, A. L., Knapper, S., McLornan, D. P., et al. (2018) · British Journal of Haematology · doi:10.1111/bjh.15648 · Cited by 180
Evaluating measurable residual disease in acute myeloid leukemia
Ravandi, F., Walter, R. B., & Freeman, S. D. (2018) · Blood Advances · doi:10.1182/bloodadvances.2018016378 · Cited by 168
Fenaux, P., Haase, D. T., Santini, V., Sanz, G. F., Platzbecker, U., & Mey, U. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.11.002 · Cited by 176
“Diagnosis of MDS is based on blood and bone marrow examination, showing blood cytopaenias, generally hypercellular (but sometimes hypocellular) marrow with dysplasia, with or without an excess of blasts.(16) Well-established diagnostic tools for MDS with widespread availability are peripheral and differential blood co…”
BackgroundInfluentialGerm line DDX41 mutations define a unique subtype of myeloid neoplasms
Makishima, H., Saiki, R., Nannya, Y., Korotev, S. C., Gurnari, C., Takeda, J., Momozawa, Y., Best, S., Krishnamurthy, P., Yoshizato, T., et al. (2022) · Blood · doi:10.1182/blood.2022018221 · Cited by 165
Self-citationMyeloproliferative neoplasms: from origins to outcomes
Nangalia, J., & Green, A. R. (2017) · Blood · doi:10.1182/blood-2017-06-782037 · Cited by 167
Primary myelofibrosis: 2017 update on diagnosis, risk‐stratification, and management
Tefferi, A. (2016) · American Journal of Hematology · doi:10.1002/ajh.24592 · Cited by 163
CD123 as a Therapeutic Target in the Treatment of Hematological Malignancies
Testa, U., Pelosi, E., & Castelli, G. (2019) · Cancers · doi:10.3390/cancers11091358 · Cited by 160
Teachey, D. T., & O’Connor, D. (2019) · Blood · doi:10.1182/blood.2019001557 · Cited by 156
Palandri, F., Breccia, M., Bonifacio, M., Polverelli, N., Elli, E. M., Benevolo, G., Tiribelli, M., Abruzzese, E., Iurlo, A., Heidel, F. H., et al. (2019) · Cancer · doi:10.1002/cncr.32664 · Cited by 156
ClinGen Myeloid Malignancy Variant Curation Expert Panel recommendations for germline RUNX1 variants
Luo, X., Feurstein, S. K., Mohan, S., Porter, C. C., Jackson, S. A., Keel, S., Chicka, M. C., Brown, A. L., Kesserwan, C. A., Agarwal, A., et al. (2019) · Blood Advances · doi:10.1182/bloodadvances.2019000644 · Cited by 158
Dworzak, M. N., Buldini, B., Gaipa, G., Ratei, R., Hrušák, O., Luria, D., Rosenthal, E., Bourquin, J., Sartor, M. M., Schumich, A., et al. (2017) · Cytometry Part B Clinical Cytometry · doi:10.1002/cyto.b.21518 · Cited by 153
Characterization and risk estimate of cancer in patients with primary Sjögren syndrome
on behalf of the SS Study Group GEAS-SEMI, Brito‐Zerón, P., Kostov, B., Fraile, G., Caravia-Durán, D., Maure, B., Rascón, F.-J., Zamora, M., Casanovas, A., López-Dupla, M., et al. (2017) · Journal of Hematology & Oncology · doi:10.1186/s13045-017-0464-5 · Cited by 153
Liquori, A., Ibáñez, M., Sargas, C., Sanz, M. Á., Barragán, E., & Cervera, J. (2020) · Cancers · doi:10.3390/cancers12030624 · Cited by 152
Brown, A. L., Arts, P., Carmichael, C., Babic, M., Dobbins, J., Chong, C., SCHREIBER, A. W., Feng, J., Phillips, K. D., Wang, P. P.-S., et al. (2020) · Blood Advances · doi:10.1182/bloodadvances.2019000901 · Cited by 151
Advances in germline predisposition to acute leukaemias and myeloid neoplasms
Klco, J. M., & Mullighan, C. G. (2020) · Nature reviews. Cancer · doi:10.1038/s41568-020-00315-z · Cited by 163
Risk of hematologic malignancies after radioiodine treatment of well-differentiated thyroid cancer
Molenaar, R. J., Sidana, S., Radivoyevitch, T., Advani, A. S., Gerds, A. T., Carraway, H. E., Angelini, D., Kalaycio, M., Nazha, A., Adelstein, D. J., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.75.0232 · Cited by 154
High prevalence of myeloid neoplasms in adults with non–Langerhans cell histiocytosis
Papo, M., Diamond, E. L., Aubart, F. C., Emile, J., Roos‐Weil, D., Gupta, N., Durham, B. H., Özkaya, N., Doǧan, A., Ulaner, G. A., et al. (2017) · Blood · doi:10.1182/blood-2017-01-761718 · Cited by 157
NCCN Guidelines Insights: Myeloproliferative Neoplasms, Version 2.2018
Mesa, R. A., Jamieson, C. H. M., Bhatia, R., Deininger, M. W., Fletcher, C. D. �., Gerds, A. T., Gojo, I., Gotlib, J. R., Gundabolu, K., Hobbs, G. S., et al. (2017) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2017.0157 · Cited by 152
Cerquozzi, S., Barraco, D., Lasho, T. L., Finke, C. M., Hanson, C. A., Ketterling, R. P., Pardanani, A. D., Gangat, N., & Tefferi, A. (2017) · Blood Cancer Journal · doi:10.1038/s41408-017-0035-6 · Cited by 152
Aggressive B-cell lymphomas in patients with myelofibrosis receiving JAK1/2 inhibitor therapy
Porpaczy, E., Tripolt, S., Hoelbl-Kovacic, A., Gisslinger, B., Bago-Horvath, Z., Casanova-Hevia, E., Clappier, E., Decker, T., Fajmann, S., Fux, D. A., et al. (2018) · Blood · doi:10.1182/blood-2017-10-810739 · Cited by 151
Lima, M. J. G. D., Oran, B., Champlin, R. E., Papadopoulos, E. B., Giralt, S. A., Scott, B. L., William, B. M., Hetzer, J., Laille, E. J., Hubbell, B., et al. (2018) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2018.06.016 · Cited by 151
Nazha, A., Narkhede, M. S., Radivoyevitch, T., Seastone, D. J., Patel, B. J., Gerds, A. T., Mukherjee, S., Kalaycio, M. E., Advani, A. S., Przychodzen, B. P., et al. (2016) · Leukemia · doi:10.1038/leu.2016.138 · Cited by 150
Pasqual, E., Schonfeld, S. J., Morton, L. M., Villoing, D., Lee, C., de González, A. B., & Kitahara, C. M. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.21.01841 · Cited by 149
“Before 2001, MDS and myeloproliferative neoplasms (MPN) were not captured in SEER.39,40 To evaluate the impact of these changes, we performed a secondary analysis of myeloid malignancies, including MDS and MPN (Data Supplement), using SEER-18 (2000-2017),41 which covers a shorter timeframe but larger US population pro…”
Method
Metadata
- Authors
- Arber, D. A., Orazi, A., Hasserjian, R., Thiele, J., Borowitz, M. J., Le Beau, M. M., Bloomfield, C. D., Cazzola, M., & Vardiman, J. W.
- Affiliations
- Stanford Medicine (US)
- Weill Cornell Medicine (US)
- Massachusetts General Hospital (US)
- University of Cologne (DE)
- Johns Hopkins Medicine (US)
- Section of Hematology/Oncology, University of Chicago, Chicago, IL;
- The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (US)
- University of Pavia (IT)
- University of Chicago (US)
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2016-05-19
- Volume
- 127
- Issue
- 20
- Pages
- 2391-2405
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W2339658711
- Cited by
- 10,119
- References
- 139
- Citations by year
- 2026: 370 · 2025: 615 · 2024: 875 · 2023: 1132 · 2022: 1265 · 2021: 1424 · 2020: 1187 · 2019: 998 · 2018: 954 · 2017: 797 · 2016: 320
- FWCI
- 145.41
- Type
- journal article
- Language
- en
- Update notices
- erratum (2016-07-21)
- Open access
- bronze
- doi.org
- Locations
- Blood (publishedVersion)
- PubMed (publishedVersion)
- Kölner Universitäts PublikationsServer (Universität zu Köln) (publishedVersion)
- Funders
- Celgene
- Incyte
- Sysmex Corporation
- Genentech
- Takeda Oncology
- Pharmacyclics
- Topics
- Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Retinoids in leukemia and cellular processes
- Health Sciences › Medicine › Hematology › Chronic Myeloid Leukemia Treatments
- Keywords
- WHO classification of hematologic neoplasms, myeloid neoplasms, acute leukemia, diagnostic criteria, prognostic factors, gene expression profiling, next-generation sequencing, immunophenotyping, morphological classification, new disease entity
- MeSH terms
- Down Syndrome, Eosinophilia, Humans, Leukemia, Myeloid, Mastocytosis, Myelodysplastic Syndromes, Myeloproliferative Disorders, World Health Organization, Oncogene Proteins, Fusion, Cell Lineage, Myeloid Cells, Genes, Neoplasm, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
